How bad is RAD-140 for your heart? The cardiac risk of RAD-140 stands unmeasured in the published studies, which leaves no ground to call the compound safe. Where the only human trial, run in women with advanced breast cancer, found mainly raised liver enzymes and gastrointestinal effects, published case reports describe serious cardiac illness after exposure outside any trial.
What those case reports contain is myocarditis, inflammation of cardiac muscle, in a teenage boy and in a young man, and heart failure in a third patient. The animals tell a different story: one study of old mice found better cardiac function, not injury. Two effects that worry readers most are known only from descriptions outside the trials: a change in cholesterol and a rise in blood pressure. No study has measured either.
The heart was never the question this compound was built to answer. RAD140 is a potent, orally bioavailable nonsteroidal selective androgen receptor modulator (SARM), which stimulates the androgen receptor as testosterone does. The rats and monkeys of its preclinical characterisation were studied for anabolic androgen action in skeletal muscle and bone, and metastatic breast cancer came much later as the clinical target. So what is RAD 140, seen from the heart? A compound that travelled from muscle and bone to breast cancer without cardiac function ever becoming its main question.
The heart and blood vessels are one strand of the safety record. Drug-induced liver injury and the suppression of the body’s own hormones belong with the other RAD 140 side effects, which the parent article covers.
Adverse events in the breast-cancer trial of vosilasarm
Nothing cardiac appeared among the most frequent adverse events of the only human trial of vosilasarm; raised liver enzymes and gastrointestinal effects led that list. The study was a first-in-human phase 1 trial and remains the only trial of RAD 140 in women: 22 heavily pretreated postmenopausal women with oestrogen receptor-positive, HER2-negative metastatic breast cancer. Daily doses of 50, 100 and 150 milligrams went to 6, 13 and 3 women respectively, and 100 milligrams a day became the maximum tolerated dose, the highest that caused no unacceptable toxicity. What they met most often was raised aspartate aminotransferase (AST), then raised alanine aminotransferase (ALT) and total bilirubin, then vomiting, dehydration, decreased appetite and weight loss; the chart below gives their rates.
For this article the list matters for what it lacks: nothing cardiac stands in it, and the page on RAD 140 and the liver follows the hepatic story. Severity, on the other hand, ran high in so sick a group: Grade 3/4 adverse events, those rated severe or life-threatening, occurred in 72.7% of the women, treatment-related adverse events in 77.3%.
[Figure 1. Most frequent adverse events in RAD140’s trial. In the only human trial of RAD140, 22 women with advanced breast cancer took 50 to 150 mg daily. Raised liver enzymes led the adverse events above 10%, followed by digestive effects, and no cardiac event appeared among them.]
Blood pressure did not figure among the frequent events. Two serum markers did show the compound acting on the androgen receptor: sex hormone-binding globulin (SHBG) fell in 18 of 18 women, and prostate-specific antigen (PSA) rose in 16 of 20. An elimination half-life of 44.7 hours was long enough for once-daily administration. Everything about this population sets it apart from the adolescent and young adult patients of the cardiac case reports: older women, advanced cancer, close clinical monitoring. Theirs is still the only human trial among the RAD-140 studies in print.
Myocarditis and heart failure in the case reports
Three case reports connect RAD-140 with serious cardiac illness, each with a different degree of certainty. A 16-year-old boy was diagnosed with myopericarditis, inflammation of the myocardium and of the pericardium that encloses it, after the first dose of a product sold as testolone; his clinicians call such effects potentially life-threatening and poorly characterised. A young man exposed outside medical supervision presented with possible acute myocarditis, which his doctors recorded as a working diagnosis rather than a settled one. In the third report the authors attribute heart failure to the same compound and file the case under catastrophic effects.
Each of these is a published description of one patient. Put together, they show that serious cardiac harm has followed exposure, in a 16-year-old and in young adults alike, and no more than that: no rate, because nobody counted the exposed, and no settled cause, because one clinical description cannot rule out other substances taken at the same time. One thing they do share is the calendar. All of them appeared between 2022 and 2024, inside three years.
How much does RAD140 raise blood pressure, and at what dose?
No controlled study has measured blood pressure under RAD140, so neither the size of any rise nor a dose at which it begins is established. Outside the published trials, high blood pressure on RAD 140 is among the cardiac effects described most often, and what the descriptions turn on is fluid balance and markers of renal function, not readings in millimetres of mercury.
In descriptions beyond the trials, dose is a poor guide: a low dose is enough to bring on these changes, and a higher one adds nothing beyond the same disturbance of fluid and electrolytes. The changes named are these:
disturbed fluid and electrolyte balance
water retention
a sensitivity to dietary sodium
a rise in creatinine, described after some weeks at a low dose
a fall in the estimated glomerular filtration rate, a calculated estimate of renal filtration
In those accounts hypertension, blood pressure persistently above guideline thresholds, differs widely in degree from one individual to the next, and what the compound contributes is hard to tell from what stimulants, other substances and diet contribute. The expectation is that a rise grows with dose and duration and settles once exposure ends, but neither pattern has been measured for RAD140, and much of the material comes from RAD140 on Reddit and YouTube.
Does RAD140 raise blood pressure in most users or only some?
Accounts outside the published studies have RAD140 raising blood pressure in some cases and leaving it alone in others, which yields no share of affected individuals. A few of them describe a rise large enough for testosterone replacement therapy (TRT), prescribed androgen treatment for low testosterone, to be weighed in place of the compound, while others record blood pressure readings for RAD 140 and TRT taken together.
Among the effects described outside the trials there is also a poor individual response to the compound, with the water retention blamed on the conversion of testosterone to oestrogen rather than on the compound. Since the accounts disagree, RAD140 is generally held not to raise blood pressure in every case; a rise counts as possible rather than predictable, and as a reason to measure more than once.
When is blood pressure on RAD140 a reason to worry?
Blood pressure during exposure to RAD140 is generally agreed to be high when repeated readings, taken at rest on separate occasions, stay above the thresholds in clinical guidelines; one raised reading says far less than a pattern. Whether a given reading matters is a doctor’s judgement, made against the individual’s own cardiovascular risk and not against a threshold alone. One combination is widely understood as a possible hypertensive emergency, calling for urgent care: a raised reading together with any of the following.
severe headache
chest pain
breathlessness
visual change
confusion
one-sided weakness
Should you check blood pressure while on RAD140, and how often?
Checking blood pressure during exposure to RAD140 is generally held to be worth doing repeatedly rather than once: paired readings morning and evening on several consecutive days, with the first day’s figures set aside. A reading counts as reliable only from a validated upper-arm cuff of the correct size, taken after some minutes of seated rest with the back supported, the feet flat and the arm at heart level.
Readings averaged in that way from a home blood pressure monitor show a sustained shift from an individual’s baseline. One reading cannot show that, because stress, recent activity or the white-coat effect (the clinic itself lifting the reading) may have raised it.
Does tadalafil (Cialis) lower blood pressure raised by RAD140?
Only slightly, as a rule. Tadalafil (Cialis) is a phosphodiesterase type 5 inhibitor: it relaxes vascular smooth muscle, and the fall in systemic blood pressure that follows is generally held too small to matter on its own. That is why the drug is licensed for erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension, raised pressure in the arteries of the lungs, and not for hypertension.
Taken with nitrates or alpha-blockers, however, tadalafil is widely described as capable of a sharp fall in blood pressure. Its effect on blood pressure is a matter of such interactions, not of control, and none of the pathways thought to carry the cardiovascular effects of SARMs such as RAD140 is one the drug acts on.
Does RAD140 raise resting heart rate?
Resting heart rate has not been shown to rise under RAD140 in any controlled human study, so the effect is generally held to be unknown rather than excluded, and the cardiac case reports describe myocarditis and heart failure, not an isolated rise in heart rate. Androgens as a group are widely understood to raise cardiac workload and to go with a greater tendency to arrhythmia, and so are the raised blood pressure and the thickening of cardiac muscle sometimes linked to them. A disturbance of that kind may present as palpitations or as tachycardia (a fast resting heart rate), and an electrocardiogram, ambulatory monitoring and an echocardiogram tell it from normal variation.
Can RAD140 cause nosebleeds?
No link between RAD140 and nosebleeds appears in the research literature. A nosebleed, or epistaxis, is generally held to come from fragile vessels in the anterior nasal cavity, most often because of dry air, minor trauma, upper respiratory tract infection, allergic rhinitis or anticoagulant and antiplatelet medicines.
Raised blood pressure is widely understood to make such bleeding heavier and longer, though whether it causes epistaxis by itself is still debated. Androgens and compounds acting on the androgen receptor are generally held to raise both blood pressure and red cell mass, and the higher red cell mass is sometimes described as adding to epistaxis. A nosebleed that is heavy, that will not stop under direct pressure, or that comes with dizziness or chest pain is held to need medical care.
What does RAD140 do to HDL and LDL cholesterol, and by how much?
Outside the published trials, RAD140 is described as pushing low-density lipoprotein (LDL) cholesterol up and high-density lipoprotein (HDL) cholesterol down. By how much? The accounts cannot say, because they give the size in words, a marked rise or a sharp fall, never as a measured quantity, and a change in cholesterol does not appear in every account, with a few describing no marked movement of either fraction.
Beyond the trial data, high LDL cholesterol and high triglycerides are described as already present before exposure, which makes any later lipid change in RAD 140 blood work, measured on a lipid panel, hard to attribute. The accounts nonetheless expect a disturbed balance between the two lipoprotein fractions as a consequence of exposure.
The class tells more than the compound. For SARMs as a class, a fall in HDL cholesterol that grows with the dose is generally held to be the rule, while the effect on LDL cholesterol is far less consistent: preclinical studies in animals describe LDL cholesterol, HDL cholesterol and triglycerides falling together, and the few human observations more often describe LDL cholesterol rising as HDL cholesterol falls. For RAD140 itself no controlled measurement of either fraction in humans exists.
What can be done about bad lipids on RAD140, and do they recover after stopping?
Whatever alters plasma lipids at all is generally held to be the way to address an adverse lipid result on RAD140: diet, body weight, physical activity, smoking, alcohol, thyroid and liver function, and lipid-lowering medicines. A doctor reads one panel against overall cardiovascular risk rather than on its own and commonly repeats an abnormal result before interpreting it. Androgen-related lipid changes are widely understood to reverse over weeks to months after exposure ends; for RAD140 in particular the recovery is not documented, and what repeated disturbance does to the vessels over the long term remains uncertain.
Do heart effects depend on dose or length of exposure?
Not one of this article’s sources ties a cardiac effect of RAD140 to a particular dose. Myopericarditis followed the first dose in the 16-year-old boy, while the breast-cancer trial gave 50 to 150 milligrams once daily for far longer and listed nothing cardiac among its frequent adverse events. In that trial blood concentrations built up over several days, since the RAD 140 half-life is longer than the gap between once-daily doses.
The animals do not resolve it either. After 6 weeks at 5 mg/kg a day, older mice, and males in particular, had better cardiac function than controls; young and adult female mice on the same daily dose for a longer run of weeks showed greater frailty and a higher mortality risk than controls. The table below sets these beside the other animal studies. What separates the results is species, sex and length of exposure far more than dose, across the RAD140 doses given in the trial and the animal studies alike.
Animal studies of RAD140 compared
Animals
Exposure in the study
Main finding
Old male and female mice, aged 23 months
5 mg/kg a day for 6 weeks
Higher ejection fraction, stroke volume and cardiac output; no structural differences
Old mice aged 23.7–25.5 months, 21 males and 15 females
5 mg/kg a day for 6 weeks
No effect on frailty; in males, preserved lean mass (p = 0.024) and lower serum interleukin-6 (p = 0.043)
Young and adult female mice
5 mg/kg for 10 weeks
Higher frailty status and mortality risk than controls (p ≤ 0.042)
Geldings (castrated male horses)
Dose and duration not given in the abstract
Raised clusterin, inflammation-linked proteins and the erythropoiesis-linked GPLD1 in plasma
Heart function in older mice given RAD140
Old mice given RAD140 pumped blood more strongly, and their hearts showed no injury. Treatment with the selective androgen receptor modulator RAD140 is linked to better cardiac function, with male-specific effects that are graded by interleukin-6, a circulating inflammatory cytokine. The animals were 23 months old and received 5 mg/kg a day for 6 weeks. On echocardiography, ultrasound imaging of the heart, treated mice showed a higher ejection fraction, the share of ventricular blood ejected per beat, together with a higher stroke volume and a higher cardiac output than controls, each by the margin in the table below.
In males the gain went further: better myocardial strain (how far the wall deforms during the beat) and a shorter isovolumic relaxation time before filling. In females those two effects were lesser or opposite. Neither sex showed structural differences, a null finding that counts against concern over cardiac enlargement, and androgen receptor mRNA was lower in the treated animals of both sexes. Higher interleukin-6 accompanied worse circumferential strain in males but not in females, whereas a companion study found lower serum interleukin-6 in treated males.
Behind this work lies a premise: low testosterone goes with poorer cardiac function and raised inflammatory markers, and the SARM RAD140 can stimulate the androgen receptor as testosterone does, which places the RAD 140 vs testosterone comparison at its centre. Old mice of either sex are a long way from the young men of the case reports.
Heart function in old mice given RAD140
Measure
Change versus controls
Sex in which it was seen
Ejection fraction
+10.4%
Males and females
Stroke volume
+9.6 µL
Males and females
Cardiac output
+4.5 mL/min
Males and females
Myocardial strain
−5.8%
Males; lesser or opposite in females
Isovolumic relaxation time
−4.7 ms
Males; lesser or opposite in females
Cardiac structure
No differences
Males and females
Frailty, survival and blood proteins in other animal studies
Two further animal studies pull the other way, towards harm and towards changes in the blood. Young and adult female mice on 5 mg/kg for 10 weeks scored higher on a frailty index of age-related health deficits and ran a higher mortality risk than controls (p ≤ 0.042), and the same young animals adapted less to repeated bouts of eccentric contractions (p = 0.040). Plasma proteomics in geldings, castrated male horses given RAD140, found clusterin raised, together with the inflammation-linked proteins haptoglobin, CD14 and ITIH4 and with GPLD1, a protein tied to the production of red blood cells (erythropoiesis).
Does RAD140 raise red blood cell count or hematocrit?
An effect of RAD140 on red blood cell count or hematocrit, the share of blood volume made up of red cells, has barely been studied, so it is generally held to be plausible rather than established. The plausibility comes from androgens, which are widely understood to raise hematocrit by driving red blood cell production, partly through more erythropoietin and partly through less hepcidin, which frees iron for new cells. Erythrocytosis (a hematocrit above the normal range) is commonly described after exposure to testosterone and to anabolic-androgenic steroids, synthetic derivatives of testosterone. SARMs are generally held to act more weakly on red blood cells, but neither that comparison for SARMs in general nor the one of RAD 140 vs steroids is well established.
Limits of the evidence on RAD140 and the heart
At every tier the evidence on how bad RAD-140 is for the heart is thin. The only human trial enrolled a small group of heavily pretreated postmenopausal women with advanced breast cancer and listed nothing cardiac among its frequent adverse events, so it cannot speak for young men. The three published case reports describe one patient each and give neither a rate nor proof of cause. The better cardiac function in the animal work was measured in old mice and has not been shown in humans.
These drugs are widely abused by physically active young adults; however, the drugs’ side effects, which can be life-threatening, are not well characterized.
Attribution is loose across all three tiers, because products sold as RAD140 have held other active compounds, or none of the declared one, and urine samples found to contain SARMs have often held several agents at once. Among the sources this article draws on there is no study of RAD-140’s effect on testosterone suppression and on lipids in healthy men. Our RAD-140 for sale is supplied for laboratory research with batch and purity data, so the compound behind a laboratory result is known.
Raised blood pressure and the shifts in LDL and HDL cholesterol are known only from descriptions outside the trials; no published study among this article’s sources has measured either effect.
No regulator has approved RAD140 or reviewed a cardiac safety dossier for it, and SARMs have been prohibited in sport since 2008, before any clinical evidence on the heart existed.
What a product sold as RAD140 holds is often not what its label says, which clouds every cardiac effect laid at the compound’s door, so RAD 140 quality is part of the question.
The rest of our UK SARMs range carries the same documentation.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
Which adverse events were most frequent in the only human trial of RAD140, in women with metastatic breast cancer?
Raised liver enzymes and gastrointestinal effects ✓
A rise in blood pressure and marked water retention
Palpitations and a raised resting heart rate
A fall in HDL and a rise in LDL cholesterol
In the phase 1 trial of 22 women, raised AST, ALT and bilirubin, vomiting and decreased appetite led the list, and no cardiac event was among them.
What did the three published case reports describe after exposure to RAD140 outside any trial?
Myocarditis in two young patients, heart failure in a third ✓
A rise in resting heart rate in a group of young men
Thickening of the heart muscle seen on echocardiography
Hypertension severe enough for urgent hospital care in each patient
A 16-year-old boy had myopericarditis, a young man possible acute myocarditis and a third patient heart failure, though single cases give no rate or proof of cause.
What did echocardiography show in old mice given RAD140 for six weeks?
A higher ejection fraction and no structural differences ✓
A thicker left ventricular wall and a lower ejection fraction
Inflammation of the heart muscle like that in the case reports
No measurable change in any measure of cardiac function
In 23-month-old mice, ejection fraction rose by 10.4%, with higher stroke volume and cardiac output and no structural differences.
Where does the account of RAD140 raising blood pressure and shifting cholesterol come from?
Accounts outside the published trials, not measurements ✓
Blood pressure and lipid readings from the breast-cancer trial
Measurements made by echocardiography in the old-mouse studies
A controlled study of RAD140 in healthy young men
No published study has measured either effect, and the only human trial did not list raised blood pressure among its most frequent adverse events.
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
How bad is RAD-140 for the heart? What the evidence shows
By Matthew Waite, MB BChir · Reviewed by Elizabeth Hyams
Published · Updated · 18 min read
The short answer on RAD140 and the heart
How bad is RAD-140 for your heart? The cardiac risk of RAD-140 stands unmeasured in the published studies, which leaves no ground to call the compound safe. Where the only human trial, run in women with advanced breast cancer, found mainly raised liver enzymes and gastrointestinal effects, published case reports describe serious cardiac illness after exposure outside any trial.
What those case reports contain is myocarditis, inflammation of cardiac muscle, in a teenage boy and in a young man, and heart failure in a third patient. The animals tell a different story: one study of old mice found better cardiac function, not injury. Two effects that worry readers most are known only from descriptions outside the trials: a change in cholesterol and a rise in blood pressure. No study has measured either.
The heart was never the question this compound was built to answer. RAD140 is a potent, orally bioavailable nonsteroidal selective androgen receptor modulator (SARM), which stimulates the androgen receptor as testosterone does. The rats and monkeys of its preclinical characterisation were studied for anabolic androgen action in skeletal muscle and bone, and metastatic breast cancer came much later as the clinical target. So what is RAD 140, seen from the heart? A compound that travelled from muscle and bone to breast cancer without cardiac function ever becoming its main question.
The heart and blood vessels are one strand of the safety record. Drug-induced liver injury and the suppression of the body’s own hormones belong with the other RAD 140 side effects, which the parent article covers.
Adverse events in the breast-cancer trial of vosilasarm
Nothing cardiac appeared among the most frequent adverse events of the only human trial of vosilasarm; raised liver enzymes and gastrointestinal effects led that list. The study was a first-in-human phase 1 trial and remains the only trial of RAD 140 in women: 22 heavily pretreated postmenopausal women with oestrogen receptor-positive, HER2-negative metastatic breast cancer. Daily doses of 50, 100 and 150 milligrams went to 6, 13 and 3 women respectively, and 100 milligrams a day became the maximum tolerated dose, the highest that caused no unacceptable toxicity. What they met most often was raised aspartate aminotransferase (AST), then raised alanine aminotransferase (ALT) and total bilirubin, then vomiting, dehydration, decreased appetite and weight loss; the chart below gives their rates.
For this article the list matters for what it lacks: nothing cardiac stands in it, and the page on RAD 140 and the liver follows the hepatic story. Severity, on the other hand, ran high in so sick a group: Grade 3/4 adverse events, those rated severe or life-threatening, occurred in 72.7% of the women, treatment-related adverse events in 77.3%.
Blood pressure did not figure among the frequent events. Two serum markers did show the compound acting on the androgen receptor: sex hormone-binding globulin (SHBG) fell in 18 of 18 women, and prostate-specific antigen (PSA) rose in 16 of 20. An elimination half-life of 44.7 hours was long enough for once-daily administration. Everything about this population sets it apart from the adolescent and young adult patients of the cardiac case reports: older women, advanced cancer, close clinical monitoring. Theirs is still the only human trial among the RAD-140 studies in print.
Myocarditis and heart failure in the case reports
Three case reports connect RAD-140 with serious cardiac illness, each with a different degree of certainty. A 16-year-old boy was diagnosed with myopericarditis, inflammation of the myocardium and of the pericardium that encloses it, after the first dose of a product sold as testolone; his clinicians call such effects potentially life-threatening and poorly characterised. A young man exposed outside medical supervision presented with possible acute myocarditis, which his doctors recorded as a working diagnosis rather than a settled one. In the third report the authors attribute heart failure to the same compound and file the case under catastrophic effects.
Each of these is a published description of one patient. Put together, they show that serious cardiac harm has followed exposure, in a 16-year-old and in young adults alike, and no more than that: no rate, because nobody counted the exposed, and no settled cause, because one clinical description cannot rule out other substances taken at the same time. One thing they do share is the calendar. All of them appeared between 2022 and 2024, inside three years.
How much does RAD140 raise blood pressure, and at what dose?
No controlled study has measured blood pressure under RAD140, so neither the size of any rise nor a dose at which it begins is established. Outside the published trials, high blood pressure on RAD 140 is among the cardiac effects described most often, and what the descriptions turn on is fluid balance and markers of renal function, not readings in millimetres of mercury.
In descriptions beyond the trials, dose is a poor guide: a low dose is enough to bring on these changes, and a higher one adds nothing beyond the same disturbance of fluid and electrolytes. The changes named are these:
In those accounts hypertension, blood pressure persistently above guideline thresholds, differs widely in degree from one individual to the next, and what the compound contributes is hard to tell from what stimulants, other substances and diet contribute. The expectation is that a rise grows with dose and duration and settles once exposure ends, but neither pattern has been measured for RAD140, and much of the material comes from RAD140 on Reddit and YouTube.
Does RAD140 raise blood pressure in most users or only some?
Accounts outside the published studies have RAD140 raising blood pressure in some cases and leaving it alone in others, which yields no share of affected individuals. A few of them describe a rise large enough for testosterone replacement therapy (TRT), prescribed androgen treatment for low testosterone, to be weighed in place of the compound, while others record blood pressure readings for RAD 140 and TRT taken together.
Among the effects described outside the trials there is also a poor individual response to the compound, with the water retention blamed on the conversion of testosterone to oestrogen rather than on the compound. Since the accounts disagree, RAD140 is generally held not to raise blood pressure in every case; a rise counts as possible rather than predictable, and as a reason to measure more than once.
When is blood pressure on RAD140 a reason to worry?
Blood pressure during exposure to RAD140 is generally agreed to be high when repeated readings, taken at rest on separate occasions, stay above the thresholds in clinical guidelines; one raised reading says far less than a pattern. Whether a given reading matters is a doctor’s judgement, made against the individual’s own cardiovascular risk and not against a threshold alone. One combination is widely understood as a possible hypertensive emergency, calling for urgent care: a raised reading together with any of the following.
Should you check blood pressure while on RAD140, and how often?
Checking blood pressure during exposure to RAD140 is generally held to be worth doing repeatedly rather than once: paired readings morning and evening on several consecutive days, with the first day’s figures set aside. A reading counts as reliable only from a validated upper-arm cuff of the correct size, taken after some minutes of seated rest with the back supported, the feet flat and the arm at heart level.
Readings averaged in that way from a home blood pressure monitor show a sustained shift from an individual’s baseline. One reading cannot show that, because stress, recent activity or the white-coat effect (the clinic itself lifting the reading) may have raised it.
Does tadalafil (Cialis) lower blood pressure raised by RAD140?
Only slightly, as a rule. Tadalafil (Cialis) is a phosphodiesterase type 5 inhibitor: it relaxes vascular smooth muscle, and the fall in systemic blood pressure that follows is generally held too small to matter on its own. That is why the drug is licensed for erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension, raised pressure in the arteries of the lungs, and not for hypertension.
Taken with nitrates or alpha-blockers, however, tadalafil is widely described as capable of a sharp fall in blood pressure. Its effect on blood pressure is a matter of such interactions, not of control, and none of the pathways thought to carry the cardiovascular effects of SARMs such as RAD140 is one the drug acts on.
Does RAD140 raise resting heart rate?
Resting heart rate has not been shown to rise under RAD140 in any controlled human study, so the effect is generally held to be unknown rather than excluded, and the cardiac case reports describe myocarditis and heart failure, not an isolated rise in heart rate. Androgens as a group are widely understood to raise cardiac workload and to go with a greater tendency to arrhythmia, and so are the raised blood pressure and the thickening of cardiac muscle sometimes linked to them. A disturbance of that kind may present as palpitations or as tachycardia (a fast resting heart rate), and an electrocardiogram, ambulatory monitoring and an echocardiogram tell it from normal variation.
Can RAD140 cause nosebleeds?
No link between RAD140 and nosebleeds appears in the research literature. A nosebleed, or epistaxis, is generally held to come from fragile vessels in the anterior nasal cavity, most often because of dry air, minor trauma, upper respiratory tract infection, allergic rhinitis or anticoagulant and antiplatelet medicines.
Raised blood pressure is widely understood to make such bleeding heavier and longer, though whether it causes epistaxis by itself is still debated. Androgens and compounds acting on the androgen receptor are generally held to raise both blood pressure and red cell mass, and the higher red cell mass is sometimes described as adding to epistaxis. A nosebleed that is heavy, that will not stop under direct pressure, or that comes with dizziness or chest pain is held to need medical care.
What does RAD140 do to HDL and LDL cholesterol, and by how much?
Outside the published trials, RAD140 is described as pushing low-density lipoprotein (LDL) cholesterol up and high-density lipoprotein (HDL) cholesterol down. By how much? The accounts cannot say, because they give the size in words, a marked rise or a sharp fall, never as a measured quantity, and a change in cholesterol does not appear in every account, with a few describing no marked movement of either fraction.
Beyond the trial data, high LDL cholesterol and high triglycerides are described as already present before exposure, which makes any later lipid change in RAD 140 blood work, measured on a lipid panel, hard to attribute. The accounts nonetheless expect a disturbed balance between the two lipoprotein fractions as a consequence of exposure.
The class tells more than the compound. For SARMs as a class, a fall in HDL cholesterol that grows with the dose is generally held to be the rule, while the effect on LDL cholesterol is far less consistent: preclinical studies in animals describe LDL cholesterol, HDL cholesterol and triglycerides falling together, and the few human observations more often describe LDL cholesterol rising as HDL cholesterol falls. For RAD140 itself no controlled measurement of either fraction in humans exists.
What can be done about bad lipids on RAD140, and do they recover after stopping?
Whatever alters plasma lipids at all is generally held to be the way to address an adverse lipid result on RAD140: diet, body weight, physical activity, smoking, alcohol, thyroid and liver function, and lipid-lowering medicines. A doctor reads one panel against overall cardiovascular risk rather than on its own and commonly repeats an abnormal result before interpreting it. Androgen-related lipid changes are widely understood to reverse over weeks to months after exposure ends; for RAD140 in particular the recovery is not documented, and what repeated disturbance does to the vessels over the long term remains uncertain.
Do heart effects depend on dose or length of exposure?
Not one of this article’s sources ties a cardiac effect of RAD140 to a particular dose. Myopericarditis followed the first dose in the 16-year-old boy, while the breast-cancer trial gave 50 to 150 milligrams once daily for far longer and listed nothing cardiac among its frequent adverse events. In that trial blood concentrations built up over several days, since the RAD 140 half-life is longer than the gap between once-daily doses.
The animals do not resolve it either. After 6 weeks at 5 mg/kg a day, older mice, and males in particular, had better cardiac function than controls; young and adult female mice on the same daily dose for a longer run of weeks showed greater frailty and a higher mortality risk than controls. The table below sets these beside the other animal studies. What separates the results is species, sex and length of exposure far more than dose, across the RAD140 doses given in the trial and the animal studies alike.
Animal studies of RAD140 compared
Heart function in older mice given RAD140
Old mice given RAD140 pumped blood more strongly, and their hearts showed no injury. Treatment with the selective androgen receptor modulator RAD140 is linked to better cardiac function, with male-specific effects that are graded by interleukin-6, a circulating inflammatory cytokine. The animals were 23 months old and received 5 mg/kg a day for 6 weeks. On echocardiography, ultrasound imaging of the heart, treated mice showed a higher ejection fraction, the share of ventricular blood ejected per beat, together with a higher stroke volume and a higher cardiac output than controls, each by the margin in the table below.
In males the gain went further: better myocardial strain (how far the wall deforms during the beat) and a shorter isovolumic relaxation time before filling. In females those two effects were lesser or opposite. Neither sex showed structural differences, a null finding that counts against concern over cardiac enlargement, and androgen receptor mRNA was lower in the treated animals of both sexes. Higher interleukin-6 accompanied worse circumferential strain in males but not in females, whereas a companion study found lower serum interleukin-6 in treated males.
Behind this work lies a premise: low testosterone goes with poorer cardiac function and raised inflammatory markers, and the SARM RAD140 can stimulate the androgen receptor as testosterone does, which places the RAD 140 vs testosterone comparison at its centre. Old mice of either sex are a long way from the young men of the case reports.
Heart function in old mice given RAD140
Frailty, survival and blood proteins in other animal studies
Two further animal studies pull the other way, towards harm and towards changes in the blood. Young and adult female mice on 5 mg/kg for 10 weeks scored higher on a frailty index of age-related health deficits and ran a higher mortality risk than controls (p ≤ 0.042), and the same young animals adapted less to repeated bouts of eccentric contractions (p = 0.040). Plasma proteomics in geldings, castrated male horses given RAD140, found clusterin raised, together with the inflammation-linked proteins haptoglobin, CD14 and ITIH4 and with GPLD1, a protein tied to the production of red blood cells (erythropoiesis).
Does RAD140 raise red blood cell count or hematocrit?
An effect of RAD140 on red blood cell count or hematocrit, the share of blood volume made up of red cells, has barely been studied, so it is generally held to be plausible rather than established. The plausibility comes from androgens, which are widely understood to raise hematocrit by driving red blood cell production, partly through more erythropoietin and partly through less hepcidin, which frees iron for new cells. Erythrocytosis (a hematocrit above the normal range) is commonly described after exposure to testosterone and to anabolic-androgenic steroids, synthetic derivatives of testosterone. SARMs are generally held to act more weakly on red blood cells, but neither that comparison for SARMs in general nor the one of RAD 140 vs steroids is well established.
Limits of the evidence on RAD140 and the heart
At every tier the evidence on how bad RAD-140 is for the heart is thin. The only human trial enrolled a small group of heavily pretreated postmenopausal women with advanced breast cancer and listed nothing cardiac among its frequent adverse events, so it cannot speak for young men. The three published case reports describe one patient each and give neither a rate nor proof of cause. The better cardiac function in the animal work was measured in old mice and has not been shown in humans.
Attribution is loose across all three tiers, because products sold as RAD140 have held other active compounds, or none of the declared one, and urine samples found to contain SARMs have often held several agents at once. Among the sources this article draws on there is no study of RAD-140’s effect on testosterone suppression and on lipids in healthy men. Our RAD-140 for sale is supplied for laboratory research with batch and purity data, so the compound behind a laboratory result is known.
Raised blood pressure and the shifts in LDL and HDL cholesterol are known only from descriptions outside the trials; no published study among this article’s sources has measured either effect.
No regulator has approved RAD140 or reviewed a cardiac safety dossier for it, and SARMs have been prohibited in sport since 2008, before any clinical evidence on the heart existed.
What a product sold as RAD140 holds is often not what its label says, which clouds every cardiac effect laid at the compound’s door, so RAD 140 quality is part of the question.
The rest of our UK SARMs range carries the same documentation.
Check what you remember
4 questions on this article; the right answer is marked.
In the phase 1 trial of 22 women, raised AST, ALT and bilirubin, vomiting and decreased appetite led the list, and no cardiac event was among them.
A 16-year-old boy had myopericarditis, a young man possible acute myocarditis and a third patient heart failure, though single cases give no rate or proof of cause.
In 23-month-old mice, ejection fraction rose by 10.4%, with higher stroke volume and cardiac output and no structural differences.
No published study has measured either effect, and the only human trial did not list raised blood pressure among its most frequent adverse events.
Matthew Waite, MB BChir · Imperial College Healthcare
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
RAD 140 teenager: what a case report and animal data show
RAD 140 teenager evidence records harm: myopericarditis in a 16-year-old boy after his first dose, and raised frailty and mortality risk in mice.
RAD 140 lethargy: mood, sleep and what the evidence shows
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
RAD 140 side effects: what the trials and case reports show
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Is MK-677 liver toxic? The liver and kidney evidence
Is MK-677 liver toxic: trials found it well tolerated, but a case report links it alone to raised liver enzymes that settled once exposure ended.